Assisted reproductive technology in Europe, 2001. Results generated from European registers by ESHRE.

ESHRE Central Office, Meerstraat 60, Grimbergen B-1852, Belgium.
Human Reproduction (Impact Factor: 4.59). 06/2005; 20(5):1158-76. DOI: 10.1093/humrep/deh755
Source: PubMed

ABSTRACT European results of assisted reproductive techniques from treatments initiated during 2001 are presented in this fifth report. Data were collected mainly from already existing national registers. From 23 countries, 579 clinics reported 289 690 cycles with: IVF 120 946, ICSI 114 378, frozen embryo transfer (FER) 47 195 and egg donation (ED) 7171. Overall this represents a 4% increase since the year 2000. For the first time, results on European data on intra-uterine inseminations (IUIs) were reported from 15 countries. A total of 67 124 cycles [IUI husband'sperm (IUI-H) 52 949 and IUI donor sperm (IUI-D) 14 185] were included. In 12 countries where all clinics reported to the register, a total of 108 910 cycles were performed in a population of 131.4 million, corresponding to 829 cycles per million inhabitants. For IVF, the clinical pregnancy rate per aspiration and per transfer was 25.1 and 29.0%, respectively. For ICSI, the corresponding rates were 26.2 and 28.3%. These figures are similar to the results from 2000. After IUI-H, the clinical pregnancy rate was 12.8% in women <40 and 9.7% in women > or =40 years of age. After IVF and ICSI, the distribution of transfer of one, two, three and > or =4 embryos was 12.0, 51.7, 30.8 and 5.5%, respectively. Compared with the year 2000, fewer embryos were transferred, but huge differences existed between countries. The distribution of singleton, twin and triplet deliveries for IVF and ICSI combined was 74.5, 24.0 and 1.5%, respectively. This gives a total multiple delivery rate of 25.5%, compared with 26.9% in the year 2000. The range of triplet deliveries after IVF and ICSI differed from 0.0 to 8.2% between countries. After IUI-H in women <40 years of age, 10.2% were twin and 1.1% were triplet gestations.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Angiogenesis, invasion and decidualization play an important role in implantation and embryo development. Matrix metalloproteinases (MMPs) are crucial for the degradation/remodeling of the extracellular matrix, and are involved in spiral artery formation and invasion of endometrium during implantation. A functional single—nucleotide polymorphism (SNP) in the MMP9 promoter, —1562C/T, is known to influence gene expression in allele—specific manner. The present study evaluated the association between maternal genotype of SNP —1562C/T of MMP9 and in vitro fertilization and embryo transfer (IVF—ET) outcome in infertile women. This case-control study was comprised of infertile patients (n= 123) and women having one healthy child as controls (n= 147). Genotyping for SNP—1562C/T was performed by PCR/RFLP. Allele and genotype distribution did not differ significantly between patients and controls (P>0.05). The MMP9 genotype frequencies amongst the 123 cases were C/C=73.17%, C/T=24.40% and T/T=2.43%; the C and T allele frequencies were 85.36% and 14.63%, respectively. The MMP9 genotype frequencies amongst the 147 controls were C/C=73.46%, C/T=20.40% and T/T=6.12%; the C and T allele frequencies were 83.67% and 16.32%, respectively. In conclusion, the results of this study indicate that SNP —1562C/T of MMP9 may not be associated with IVF—ET outcome in this population.
    Cellular and molecular biology (Noisy-le-Grand, France) 01/2015; 61(1):64-7. · 1.46 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In countries with comparable levels of development and healthcare systems, preterm birth rates vary markedly - a range from 5 to 10% among live births in Europe. This review seeks to identify the most likely sources of heterogeneity in preterm birth rates, which could explain differences between European countries. Multiple risk factors impact on preterm birth. Recent studies reported on measurement issues, population characteristics, reproductive health policies as well as medical practices, including those related to subfertility treatments and indicated deliveries, which affect preterm birth rates and trends in high-income countries. We showed wide variation in population characteristics, including multiple pregnancies, maternal age, BMI, smoking, and percentage of migrants in European countries. Many potentially modifiable population factors (BMI, smoking, and environmental exposures) as well as health system factors (practices related to indicated preterm deliveries) play a role in determining preterm birth risk. More knowledge about how these factors contribute to low and stable preterm birth rates in some countries is needed for shaping future policy. It is also important to clarify the potential contribution of artifactual differences owing to measurement.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.
    Current Opinion in Obstetrics and Gynecology 02/2015; 27(2). DOI:10.1097/GCO.0000000000000156 · 2.37 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Currently, the methods available for preimplantation genetic diagnosis (PGD) of in vitro fertilized (IVF) embryos do not detect de novo single-nucleotide and short indel mutations, which have been shown to cause a large fraction of genetic diseases. Detection of all these types of mutations requires whole-genome sequencing (WGS). In this study, advanced massively parallel WGS was performed on three 5- to 10-cell biopsies from two blastocyst-stage embryos. Both parents and paternal grandparents were also analyzed to allow for accurate measurements of false-positive and false-negative error rates. Overall, >95% of each genome was called. In the embryos, experimentally derived haplotypes and barcoded read data were used to detect and phase up to 82% of de novo single base mutations with a false-positive rate of about one error per Gb, resulting in fewer than 10 such errors per embryo. This represents a ∼100-fold lower error rate than previously published from 10 cells, and it is the first demonstration that advanced WGS can be used to accurately identify these de novo mutations in spite of the thousands of false-positive errors introduced by the extensive DNA amplification required for deep sequencing. Using haplotype information, we also demonstrate how small de novo deletions could be detected. These results suggest that phased WGS using barcoded DNA could be used in the future as part of the PGD process to maximize comprehensiveness in detecting disease-causing mutations and to reduce the incidence of genetic diseases. © 2015 Peters et al.; Published by Cold Spring Harbor Laboratory Press.
    Genome Research 02/2015; DOI:10.1101/gr.181255.114 · 13.85 Impact Factor